BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

3SBio Reports 7.5% YoY Revenue Growth and 25.2% Jump in Profit for 2022

New drugs started to embrace a commercialization wave, and license-out and license-in partnerships geared up. Revenue in 2022 increased by 7.5% year on yea...

March 22, 2023 | News

Jacobio Collaborates to Evaluate JAB-BX102 with KEYTRUDA® for Cancer Patients.

Jacobio Pharma (1167.HK) announced it has entered into a clinical collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate the combinatio...

March 22, 2023 | News

Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease

Huntington's disease is a debilitating genetic disorder that affects the brain, causing gradual degeneration of nerve cells in specific areas of the brain,...

March 20, 2023 | News

Glenmark's GRC 54276 IND application accepted by US FDA for first-in-human study on advanced tumors

Glenmark Specialty SA, the subsidiary of Glenmark Pharmaceuticals Ltd., an innovation-driven, global pharmaceuticals company received acceptance from the U...

March 17, 2023 | News

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeu...

March 16, 2023 | News

FDA approves Abbisko Therapeutics' Pimicotinib for Phase III clinical trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered a...

March 16, 2023 | News

Simcere Zaiming partners with Merck for SIM0235 clinical trial in advanced tumors and lymphoma

Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an in...

March 15, 2023 | News

Revolutionizing Drug Development: How AI is Reducing Time and Costs of Bringing New Treatments to Market

The development of new drugs is a lengthy and costly process that can take several years and cost billions of dollars. However, the emergence of artificial...

March 10, 2023 | Opinion

Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial

Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transfo...

March 09, 2023 | News

Debiopharm Acquires Global Rights for Novo Nordisk's USP1 Inhibitor Development.

Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow's standard-of-care treatments to cure can...

March 02, 2023 | News

Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets

Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltr...

February 22, 2023 | News

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

February 18, 2023 | News

Inventia Life Science collaborates with MSD to develop 3D advanced cell models

Collaboration to develop 3D in vitro models of the brain for the discovery of therapeutic candidates using Inventia's novel 3D cell culture platform, RASTR...

February 16, 2023 | News

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CR...

February 15, 2023 | News

Stay Connected